Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya

Kagucia, E. Wangeci; Gitonga, John N.; Kalu, Catherine; Ochomo, Eric; Ochieng, Benard; Kuya, Nickline; Karani, Angela; Nyagwange, James; Karia, Boniface; Mugo, Daisy; Karanja, Henry; Tuju, James; Mutiso, Agnes; Maroko, Hosea; Okubi, Lucy; Maitha, Eric; Ajuck, Hossan; Bogita, Mary; Mudindi, Richmond; Mukabi, David; Moracha, Wycliffe; Bulimu, David; Andanje, Nelson; Shiraku, Evans; Okuku, Rosemary; Ogutu, Monicah; Aman, Rashid; Mwangangi, Mercy; Amoth, Patrick; Kasera, Kadondi; Ng’ang’a, Wangari; Mariga, Rodgers; Munabi, Tobias; Ramadhan, Susan M; Mwikali, Janet; Nasike, Rose; Andera, Cornelius; Nechesa, Roselyne; Kiplagat, Benson K; Omengo, Julius; Oteba, Simon; Mwangi, Arthur; Mkanyi, Dorcas; Karisa, George; Migosi, Judith K; Msili, Patrick; Mwambire, Samson; Boniface, A.; Nyaguara, Amek; Voller, Shirine; Otiende, Mark; Bottomley, Christian; Agoti, Charles N.; Ochola‐Oyier, Lynette Isabella; Adetifa, Ifedayo; Etyang, Anthony; Gallagher, Katherine E.; Uyoga, Sophie; Barasa, Edwine; Bejon, Philip; Tsofa, Benjamin; Agweyu, Ambrose; Warimwe, George M.; Scott, J. Anthony G.

doi:10.1101/2021.02.12.21251294

Cited by 12 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, three were from Nigeria. 17 , 18 , 19 Two were conducted in each of the following countries: Republic of South Africa, 20 , 21 Ethiopia, 22 , 23 Libya 24 , 25 Kenya 26 and Democratic Republic of Congo (DRC). 27 One study was conducted in each of the following countries: Malawi, 28 Togo, 29 Ivory Coast, 30 Zambia, 31 Egypt, 32 Gabon, 33 Congo Brazaville, 34 South Sudan, 35 Cameroon 36 , 37 and Guinea Bissau.…”

Section: Resultsmentioning

confidence: 99%

“…The study participants in 10 studies were recruited from the general population, 18 , 22 , 23 , 24 , 31 , 32 , 33 , 34 , 35 , 36 four studies were from health workers, 17 , 27 , 28 , 38 one study combined health workers and community, 25 one study combined health workers, air transport, police and drivers, 29 three studies recruited blood donors, 19 , 20 , 39 one study recruited water front workers, 21 one study involved travelers, 40 one study recruited drivers and their assistants, 26 while the other one recruited gold miners. 30 All studies were conducted in the period between April 2020 and April 2021 except one study by Olayanju et al.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis

Chisale

Ramazanu

Mwale

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

We estimated the seroprevalence of anti‐severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre‐prints that reported anti‐SARS‐CoV‐2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were evaluated using Joana Briggs Institute prevalence critical appraisal tool. Twenty‐three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa was 22% (95%CI: 14–31) with very high heterogeneity ( I 2 = 100%, p < 0.001). Seroprevalence was highest in studies conducted in Central Africa compared to Southern Africa, West Africa, North Africa and East Africa respectively. The number of days between the first reported coronavirus disease 2019 case in each country and when a seroprevalence study was conducted was a significant moderator of seroprevalence. Seropositivity was numerically influenced by gender and age of the participants with males and those aged below 50 years being most affected with SARS‐CoV‐2 infection. The highest pooled seroprevalence in Africa reported in this review should be interpreted cautiously due to high heterogeneity between studies. Continued seroprevalence surveillance is warranted to establish Africa's transition towards herd immunity.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis

Chisale

Ramazanu

Mwale

et al. 2021

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…For example, seroprevalence was 50% among women attending ante-natal care (ANC) in August 2020 in Nairobi but 1.3%, 1.5% and 11.0% among women attending ANC in Kilifi (Coast) in September, October and November, respectively 14 . Seroprevalence among truck drivers at two sites (in Coast and Western) was 42% in October 2020 15 and seroprevalence among health care workers in between August and November 2020 was 43%, 12% and 11% in Nairobi, Busia (Western) and Kilifi (Coast), respectively 16 .…”

Section: Resultsmentioning

confidence: 99%

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

et al. 2021

Self Cite

View full text Add to dashboard Cite

Observed SARS-CoV-2 infections and deaths are low in tropical Africa raising questions about the extent of transmission. We measured SARS-CoV-2 IgG by ELISA in 9,922 blood donors across Kenya and adjusted for sampling bias and test performance. By 1st September 2020, 577 COVID-19 deaths were observed nationwide and seroprevalence was 9.1% (95%CI 7.6-10.8%). Seroprevalence in Nairobi was 22.7% (18.0-27.7%). Although most people remained susceptible, SARS-CoV-2 had spread widely in Kenya with apparently low associated mortality.

show abstract

“…For countries that experienced double wave SARS-CoV-2 epidemics, it has been challenging to quantify the relative magnitude of these waves due to the time required to scale up PCR-based diagnostic testing 36 . Furthermore, there are many epidemiological settings where it is unknown if SARS-CoV-2 transmission was constant over time, or occurred as distinct epidemic waves 5 .…”

Section: Discussionmentioning

confidence: 99%

“…Although no substitute for health systems surveillance, sero-prevalence studies have the advantage of accounting for asymptomatic cases, and symptomatic individuals who do not present to health systems. Sero-prevalence studies also provide information on the status of SARS-CoV-2 epidemics in situations where record keeping by health systems is not possible 5 .…”

Section: Introductionmentioning

confidence: 99%

Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins

Woudenberg

Rosado

Donnadieu

et al. 2021

Preprint

View full text Add to dashboard Cite

Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) induces a complex antibody response that varies by orders of magnitude between individuals and over time. Waning antibody levels lead to reduced sensitivity of serological diagnostic tests over time. This undermines the utility of serological surveillance as the SARS-CoV-2 pandemic progresses into its second year. Here we develop a multiplex serological test for measuring antibodies of three isotypes (IgG, IgM, IgA) to five SARS-CoV-2 antigens (Spike (S), receptor binding domain (RBD), Nucleocapsid (N), Spike subunit 2, Membrane-Envelope fusion) and the Spike proteins of four seasonal coronaviruses. We measure antibody responses in several cohorts of French and Irish hospitalized patients and healthcare workers followed for up to eleven months after symptom onset. The data are analysed with a mathematical model of antibody kinetics to quantify the duration of antibody responses accounting for inter-individual variation. One year after symptoms, we estimate that 36% (95% range: 11%, 94%) of anti-S IgG remains, 31% (9%, 89%) anti-RBD IgG remains, and 7% (1%, 31%) anti-N IgG remains. Antibodies of the IgM isotype waned more rapidly, with 9% (2%, 32%) anti-RBD IgM remaining after one year. Antibodies of the IgA isotype also waned rapidly, with 10% (3%, 38%) anti-RBD IgA remaining after one year. Quantitative measurements of antibody responses were used to train machine learning algorithms for classification of previous infection and estimation of time since infection. The resulting diagnostic test classified previous infections with 99% specificity and 98% (95% confidence interval: 94%, 99%) sensitivity, with no evidence for declining sensitivity over the time scale considered. The diagnostic test also provided accurate classification of time since infection into intervals of 0 - 3 months, 3 - 6 months, and 6 - 12 months. Finally, we present a computational method for serological reconstruction of past SARS-CoV-2 transmission using the data from this test when applied to samples from a single cross-sectional sero-prevalence survey.

show abstract

Seroprevalence of anti-SARS-CoV-2 IgG antibodies among truck drivers and assistants in Kenya

Cited by 12 publications

References 23 publications

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in Africa: A systematic review and meta‐analysis

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya

Serological reconstruction of COVID-19 epidemics through analysis of antibody kinetics to SARS-CoV-2 proteins

Contact Info

Product

Resources

About